Linked Life Data

7752673

Source:http://linkedlifedata.com/resource/pubmed/id/7752673

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1995-6-22
pubmed:abstractText
A drug resistant series of sublines were developed by treating the human leukaemia CCRF-CEM cell line with 16-1000 ng/ml of the anthracycline, epirubicin. The sublines developed resistance in two stages, neither involving detectable levels of P-glycoprotein. Treatment with up to 50 ng/ml epirubicin produced sublines with cross resistance limited to the anthracyclines and etoposide. Treatment with 100-1000 ng/ml epirubicin produced sublines with increased expression of the mrp gene, increased resistance to the anthracyclines and etoposide, additional cross resistance to vincristine and colchicine, decreased drug accumulation and reversal of resistance by verapamil and by buthionine sulphoximine (BSO; an inhibitor of glutathione synthesis). Our results indicate an interaction between MRP and glutathione metabolism as a mechanism for multidrug resistance.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0145-2126
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:geneSymbol
mrp
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
275-82
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line.
pubmed:affiliation
Bill Walsh Cancer Research Laboratories, Department of Clinical Oncology, Royal North Shore Hospital, St. Leonards, Australia.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't